Norzimelidine, a metabolite of a highly selective 5-hydroxytryptamine uptake inhibitor, can inhibit the uptake of noradrenaline in-vivo.
Zimelidine and norzimelidine were tested for their ability to counteract reserpine (2.5 mg kg-1)- or apomorphine (1-16 mg kg-1)-induced hypothermia and to potentiate TRH (40 mg kg-1)-induced hyperthermia in mice. Norzimelidine produced positive results in all three tests, behaving like a weak NA uptake inhibitor. Zimelidine was practically inactive. We conclude that the weak inhibitory effect of norzimelidine on the uptake of NA (in-vitro experiments) may be of importance for its pharmacological action and for the clinical action of zimelidine.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects*; D015283:Citalopram; D008297:Male; D051379:Mice; D009638:Norepinephrine / Q000378:metabolism*; D011437:Propylamines / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D015031:Zimeldine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000928:Antidepressive Agents; D011437:Propylamines; D015283:Citalopram; D015031:Zimeldine; C017578:norzimelidine; D013973:Thyrotropin-Releasing Hormone; D012110:Reserpine; D001058:Apomorphine; D009638:Norepinephrine